Institut National D Excellence En Sant Et Services Sociaux Iness

This book charts the ways in which psychoanalytic psychotherapy has been implemented, developed and researched within the public sectors of twelve different countries around the world. It discusses how psychoanalytic practitioners locally have responded to the challenge of evidence-based practice. For each country the authors describe: • How people can access talking therapies as part of the national healthcare system, including a brief history of how this system has developed and the place of psychoanalytic psychotherapy inside/outside of this system historically • How clinicians train and qualify as a psychoanalytic practitioner, and demographic profiles of their communities of psychoanalytic practice • How evidence-based practice has impacted the mental health system and, in particular, access to and provision of talking therapies e.g. through the development and implementation of treatment guidelines • How outcome monitoring and reporting of access, waiting times and recovery rates are used in the commissioning and provision of psychological therapies • What is needed to secure a viable future for psychoanalytic psychotherapy The first of two volumes, this book will be of great interest to all practicing psychoanalysts and psychoanalytic psychotherapists. The chapters in these volumes were originally published as special issues of Psychoanalytic Psychotherapy.

Patient-oriented approaches to healthcare management have been brought to the fore in recent years, yet this book underlines how even further change is needed in order to fully mobilise the experiential knowledge of patients, and ultimately improve our healthcare systems. With contributions from scholars and patients across the globe, this collection brings together a comprehensive overview of major achievements in patient engagement, analysing political, organizational and clinical contexts. By understanding the concept of care partnership, the authors explore how this patient revolution could transform, improve and innovate the ways in which care services are organized and delivered. Looking closely at the role of new technologies, this timely book will undoubtedly be of use to patients, managers and professionals within the healthcare industry, as well as those researching health policy and organization.

Resistant bacterial infections kill an estimated 1.27 million people every year. In 2018, about one million bacterial infections were reported in Canada, a quarter of which were resistant to first-line treatments. Resistant infections were responsible for more than 14,000 deaths at a cost to the healthcare system of more than $2 billion (see When Antibiotics Fail). Effective antimicrobials enable much of modern healthcare, including surgeries, transplants, and cancer treatments. People with compromised immune systems are particularly dependent on a reliable supply of effective antimicrobials to manage infections. There is an urgent need for new and accessible antimicrobial treatments to ensure sustained life-saving effectiveness of antimicrobials in the face of rising antimicrobial resistance (AMR). However, few novel antimicrobials are coming to market, and of those that do, many do not seek approval in Canada. Overcoming Resistance explores the challenges Canada faces when accessing high-value antimicrobials and describes pull incentives that could help bring existing antimicrobials to market and encourage the development of new ones. The report also analyzes the role of complementary policies relating to R&D, regulatory review, surveillance, and diagnostics, which all have the potential to enhance the impact of a pull incentive.

Islamophobia as a Form of Radicalisation discusses the scope and fragmented boundaries of Islamophobia as a concept and a sociopolitical reality. The fifteen chapters of this collection cover and connect interdisciplinary research, media content analysis, media discourse analysis, ethnographic research, intersectoral advocacy work, and action research conducted in Belgium, Canada, France, Germany, Poland, Portugal, and Spain. Confronted with an Islamophobia that is growing as a symptom of broader societal malaise in the West, a resistance against it is also arising. It is now a question of better understanding the foundations and mechanisms of this metasolidarity and resistance. Islamophobia as a Form of Radicalisation offers recommendations for urgent consideration by Muslim citizens of Canada and Europe, media professionals, civil society and academic stakeholders, policymakers at the municipal, provincial and federal levels.

Public debate on the rising cost of new biotechnology drug treatments has intensified over the last few years as healthcare budget pressures have mounted under a strained economy. Meanwhile, the demand for new, effective medical and drug treatments continues to rise as unhealthy lifestyles cause further increases in diabetes and cardiovascular disease. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death? Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences, from healthcare industry professionals to policy makers and the broader public, to gain a better understanding of this highly complex and emotionally charged field. The Price of Global Health is recognized as a valued and unique reference book that covers a complete array of topics related to global pharmaceutical pricing. It contains an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much-needed and invaluable resource for anybody interested or involved in, or affected by, the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs. The second edition includes new chapters on payer value story development, oncology, orphan drugs and payer negotiations. Furthermore, many country chapters have been substantially updated to reflect changes in the healthcare systems, including the Affordable Care Act in the US, AMNOG in Germany, medico-economic requirements in France and many other country-specific changes. Lastly, almost every chapter has been updated with new examples and illustrations.